Related Experiment Videos
New drugs in recurrent high grade gliomas
A A Brandes1, L M Pasetto, S Monfardini
1Divisione di Oncologia Medica, Azienda Ospedale, Università, Padova, Italia. brandes@ux1.unipd.it
Anticancer Research
|August 6, 2000
Summary
New chemotherapy drugs show promise for recurrent brain tumors, with temozolomide offering encouraging results. Clinical trials are crucial for developing improved treatments for malignant gliomas.
Area of Science:
- Neuro-oncology
- Clinical pharmacology
Background:
- Central Nervous System (CNS) neoplasias affect 3.8-5.1 per 100,000 people.
- Recurrent CNS tumors present significant treatment challenges.
- Current chemotherapy for recurrent tumors offers limited palliative response.
Purpose of the Study:
- To analyze novel chemotherapy drugs for recurrent CNS neoplasias.
- To evaluate objective response, time to progression (TTP), and median survival time (MST).
Main Methods:
- Review of recently introduced drugs for CNS neoplasia treatment.
- Analysis of clinical trial data focusing on efficacy and tolerability.
Main Results:
- Temozolomide demonstrates the most promising outcomes to date.
- Temozolomide is recognized as a highly active and well-tolerated agent.
- Encouraging objective response, TTP, and MST reported with temozolomide.
Conclusions:
- Novel chemotherapy strategies are essential for malignant gliomas.
- Patient enrollment in clinical trials is vital for advancing treatment knowledge.
- Investigational therapies in well-designed trials may improve outcomes for patients.